Related references
Note: Only part of the references are listed.Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin
D. Huertas et al.
ONCOGENE (2012)
A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types
Stephen Jamieson et al.
BIOCHEMICAL JOURNAL (2011)
Signal transduction by vascular endothelial growth factor receptors
Sina Koch et al.
BIOCHEMICAL JOURNAL (2011)
Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer
Toyoaki Hida et al.
CANCER SCIENCE (2011)
Vandetanib Improves Anti-Tumor Effects of L19mTNFα in Xenograft Models of Esophageal Cancer
Marika Crescenzi et al.
CLINICAL CANCER RESEARCH (2011)
Biological Potential and Structure-Activity Relationships of Most Recently Developed Vascular Disrupting Agents: An Overview of New Derivatives of Natural Combretastatin A-4
M. Marrelli et al.
CURRENT MEDICINAL CHEMISTRY (2011)
Pharmacokinetic evaluation of vadimezan (ASA404, 5,6-dimethylxanthenone-4-acetic acid, DMXAA)
Michael B. Jameson et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2011)
c-FMS inhibitors: a patent review
Christopher J. Burns et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2011)
Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non-Small-Cell Lung Cancer
Primo N. Lara et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Clinical Development of Vascular Disrupting Agents: What Lessons Can We Learn From ASA404?
Patricia M. LoRusso et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
18F-Fluromisonidazole PET Imaging as a Biomarker for the Response to 5,6-Dimethylxanthenone-4-Acetic Acid in Colorectal Xenograft Tumors
Christoph Oehler et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Monitoring Sunitinib-Induced Vascular Effects to Optimize Radiotherapy Combined with Soy Isoflavones in Murine Xenograft Tumor
Gilda Gali Hillman et al.
TRANSLATIONAL ONCOLOGY (2011)
For better or for worse: the role of Pim oncogenes in tumorigenesis
Martijn C. Nawijn et al.
NATURE REVIEWS CANCER (2011)
A Phosphodiesterase-5 Inhibitor Vardenafil Enhances Angiogenesis Through a Protein Kinase G-Dependent Hypoxia-Inducible Factor-1/Vascular Endothelial Growth Factor Pathway
Makoto Sahara et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug design
Charlotte A. Dodson et al.
BIOCHEMICAL JOURNAL (2010)
Emergence of protein kinase CK2 as a key target in cancer therapy
Janeen H. Trembley et al.
BIOFACTORS (2010)
Phase II Study on the Addition of ASA404 (Vadimezan; 5,6-Dimethylxanthenone-4-Acetic Acid) to Docetaxel in CRMPC
Roberto Pili et al.
CLINICAL CANCER RESEARCH (2010)
Aurora Kinase Inhibitors - Rising Stars in Cancer Therapeutics?
Altaf A. Dar et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2
Giorgio Cozza et al.
BIOCHEMICAL JOURNAL (2009)
Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinase
Victor J. Cee et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Trk Receptor Expression and Inhibition in Neuroblastomas
Garrett M. Brodeur et al.
CLINICAL CANCER RESEARCH (2009)
Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging
James P. B. O'Connor et al.
CLINICAL CANCER RESEARCH (2009)
Effects of sunitinib on tumor hemodynamics and delivery of chemotherapy
Marcus Czabanka et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
MRI-based characterization of vascular disruption by 5,6-dimethylxanthenone-acetic acid in gliomas
Mukund Seshadri et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2009)
Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800 mg/m2 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer
Mark J. McKeage et al.
LUNG CANCER (2009)
The Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid Improves the Antitumor Efficacy and Shortens Treatment Time Associated with Photochlor-sensitized Photodynamic Therapy In Vivo
Mukund Seshadri et al.
PHOTOCHEMISTRY AND PHOTOBIOLOGY (2009)
Acute Vascular Disruption by 5,6-Dimethylxanthenone-4-Acetic Acid in an Orthotopic Model of Human Head and Neck Cancer
Mukund Seshadri et al.
TRANSLATIONAL ONCOLOGY (2009)
Transient Retinal Effects of 5,6-Dimethylxanthenone-4-acetic Acid (DMXAA, ASA404), an Antitumor Vascular-Disrupting Agent in Phase I Clinical Trials
Michael B. Jameson et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2009)
Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer
M. J. McKeage et al.
BRITISH JOURNAL OF CANCER (2008)
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases
Beth Apsel et al.
NATURE CHEMICAL BIOLOGY (2008)
The selectivity of protein kinase inhibitors: a further update
Jenny Bain et al.
BIOCHEMICAL JOURNAL (2007)
Discovery of novel Benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors
Masaichi Hasegawa et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial
M. B. Jameson et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
Liangli Zhao et al.
INVESTIGATIONAL NEW DRUGS (2007)
New derivatives of xanthenone-4-acetic acid:: Synthesis, pharmacological profile and effect on TNF-α and NO production by human immune cells
Silvia Gobbi et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2006)
Vesicular trafficking of tyrosine kinase receptors and associated proteins in the regulation of signaling and vascular function
S Mukherjee et al.
CIRCULATION RESEARCH (2006)
5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent
M McKeage et al.
CLINICAL CANCER RESEARCH (2006)
The oncogenic properties of mutant p110α and p110β phosphatidylinositol 3-kinases in human mammary epithelial cells
JJ Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability
LL Zhao et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors
Y Miyazaki et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2005)
Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors
PA Harris et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Relationship between tumour enclothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice
LM Ching et al.
BRITISH JOURNAL OF CANCER (2004)
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
CG Willett et al.
NATURE MEDICINE (2004)
Identification of Flk-1 target genes in vasculogenesis: Pim-1 is required for endothelial and mural cell differentiation in vitro
A Zippo et al.
BLOOD (2004)
Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent
MB Jameson et al.
BRITISH JOURNAL OF CANCER (2003)
5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study
GJS Rustin et al.
BRITISH JOURNAL OF CANCER (2003)
Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging
SM Galbraith et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
In vivo imaging of embryonic vascular development using transgenic zebrafish
ND Lawson et al.
DEVELOPMENTAL BIOLOGY (2002)
Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid
LM Ching et al.
BRITISH JOURNAL OF CANCER (2002)
Share Paper
